Provider review
Longevixx Review: Four Peptides, No Lab Results, No Pharmacy Named
Longevixx's peptide menu is four products — tesamorelin, sermorelin, NAD+ and PT-141 — sold beside its GLP-1 programs, every one priced on a public page before you answer a single question. What it does not publish is anything a buyer could use to check them. There is no certificate of analysis anywhere on the site. Its pages say its medicines are prepared by licensed U.S. compounding pharmacies, but not one is named, and the words 503A and 503B never appear. Two of the four molecules have completed phase 3 trials; both were run in patients unlike the adults this menu is written for.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit LongevixxOf Longevixx’s 4 dated product claims documented below, 0 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Four peptides, two of them backed by completed phase 3 trials in patients unlike most buyers, sold with no certificate of analysis and no named pharmacy behind any of them.
Worth trusting if
- You have already decided on one of its four peptides and want the price before the questionnaire
- You want tesamorelin or PT-141, the two products here with completed phase 3 trials
- You are comfortable with a company that names no pharmacy and publishes no test result
Be skeptical if
- You want to read a certificate of analysis, because this site publishes none
- You want to know which pharmacy compounds your prescription, which it never says
- You want room to change your mind: an order can be canceled only within 24 hours, and dispensed medication is not refunded
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Longevixx
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — $249/mo, quoted as a floor rather than a rate.
- NAD+ Injection — $199/mo, the lowest price on the peptide menu. The GLP-1 microdose plan starts lower.
- Tesamorelin — $299/mo, the highest price on the peptide menu.
- PT-141 — $249/mo, the only product in Longevixx's sexual-health category.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 4 products reviewed here. The evidence concerns the molecule, not Longevixx's service.
4
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Longevixx’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
About the tesamorelin
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“A GHRH analog that asks your own pituitary to release growth hormone on its natural nightly schedule — rather than replacing the hormone from outside. […] Because that signal normally crests during deep sleep, Sermorelin is most often used to support restorative rest, recovery, and the sense of vitality that can soften with age.”
Read on the Longevixx site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
The first sentence is the tested part. Sermorelin prompts the pituitary to release its own growth hormone, and that is what all 19 randomized trials measured. The second sentence is what the product is sold for — restorative rest, recovery and vitality — and none of those was an outcome in any of them. A buyer has no way to tell where the evidence stops, and on this site no certificate exists to tell them what is in the vial either.1
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Not a peptide but a coenzyme your cells run on — NAD+ replenishes the electron-carrying fuel that quietly thins as the decades add up. […] May support steadier day-long physical and mental energy”
Read on the Longevixx site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
"Replenishes" and "steadier day-long physical and mental energy" are precisely the outcomes an injected NAD+ trial would need to measure, and none has reported. The literature usually offered in support is about oral precursors, which are different molecules taken a different way. It is the lowest-priced product on the peptide menu and the one with the least behind it.2
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“The stabilized GHRH analog studied specifically for the deep abdominal fat that resists diet and training. […] Aims to support a leaner waistline and body composition”
Read on the Longevixx site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
This is the best-evidenced molecule on the menu and its evidence is about someone else. "Studied specifically for the deep abdominal fat" is true: two completed phase 3 trials, 675 participants, measured visceral fat. But they enrolled people with HIV-associated lipodystrophy, a condition with its own specific pathology — not adults whose belly fat "resists diet and training". The page never mentions that population, so the extrapolation happens without the reader seeing it.3,4
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“The peptide that starts in the brain rather than the bloodstream — PT-141 is studied for the melanocortin pathways tied to sexual desire, in women and men alike. […] Explored for low libido in both women and men”
Read on the Longevixx site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
The women's half of "in women and men alike" rests on 1,437 participants across two phase 3 trials, which is why an approved product exists. The men's half rests on nothing in that record — the RECONNECT trials enrolled premenopausal women with hypoactive sexual desire disorder and nobody else. Longevixx names the molecule as bremelanotide but never mentions that an approved version of it is on the market.5
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on this site. Each peptide page says "Longevixx protocols are prepared by licensed compounding pharmacies in the United States" and that therapy "is prepared by a partner compounding pharmacy", the homepage says "Prepared by licensed U.S. compounding pharmacies", and the terms refer to "the Pharmacy" as a party — but none of them says which one, and "503A" and "503B" appear on no page. The site-wide disclaimer adds only that practitioners "may prescribe custom-compounded formulations prepared by licensed pharmacies". No prescriber, medical group or telehealth platform is named either; the terms speak of "Medical Groups" and "Providers" without naming any.
Read on the Longevixx site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Nothing. No page on the site mentions a "certificate of analysis" or "COA", and no potency, purity or sterility result appears anywhere. The closest thing to a quality statement is a line on each peptide page that compounding pharmacies "are regulated by state boards and the FDA" — a description of the category, not a result for any product Longevixx sells.
Licensing
Licensed to dispense, and where
Coverage
Longevixx says three ways on its homepage that it covers 50 states — a ticker, a stat block and a badge strip — and its about page repeats "50 States served". Its own contact page says something narrower: "Longevixx operates via telehealth in the states where it is licensed", and its treatment FAQs say "across the states where we're available". No exclusion list is published either way.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" at the top of the peptides page, with no license number, prescriber or medical group published anywhere on the domain.
Read on the Longevixx site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Every product is priced on a public page before any questionnaire, the GLP-1 plans included.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
- It does not claim testing it cannot show. Several sellers assert third-party testing with nothing behind it; Longevixx makes no testing claim at all, which is at least consistent.
Show 4 more
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials, and the tesamorelin page describes the mechanism accurately even where it overreaches on the population.
- The homepage promise of "$0 if you're not approved" is backed in the terms, which list a refund when "The prescribing Provider declines to issue a prescription."
- Every product page states that a licensed provider reviews the request, so nothing is presented as available without a prescription.
- No FDA warning letter for the company under any spelling of its name.
- No certificate of analysis exists anywhere on the site — no potency, purity or sterility result for any product.
- No pharmacy is named. The site says its medicines are prepared by "licensed compounding pharmacies in the United States" and never says which, or whether they are 503A or 503B.
- No prescriber or medical group is named either, on a site selling prescription-only molecules.
Show 3 more
- Refunds are narrow. An order can be canceled only within 24 hours, medication already dispensed is not refunded, and returned medication carries a $35 disposal fee.
- All four peptide claims reach past their trials, and injected NAD+ has no trial at all for the energy it is sold for.
- "Telehealth in 50 states" on the homepage against "in the states where it is licensed" on its own contact page, with no exclusion list to reconcile them.
Verdict
The bottom line
The menu is short and the prices are public, which is more than many sellers manage. What you cannot do is check what you are buying: there is no certificate of analysis, no named pharmacy and no named prescriber, and once medication ships it is yours. On the evidence itself, tesamorelin and PT-141 are the only two products with completed phase 3 trials, and both were tested in populations you are unlikely to be in.
Opens Longevixx's website. A link is not a recommendation to take anything.
What Longevixx sells
Longevixx's peptides page lists four products beside its GLP-1 programs: tesamorelin at $299 a month, sermorelin at $249, PT-141 at $249, and NAD+ at $199. Every figure is a "from" price, and every one is on a public page before the questionnaire starts. The GLP-1 plans are priced the same way.
Each product has its own page with a mechanism section, a candidacy list, a timeline and a safety note. They are well written. What none of them contains is anything you could use to check the product itself.
Full analysis — 4 more sectionsWhat is not published · What the refund terms say · What the trials show · What this means if you are buying
What is not published
No certificate of analysis. No pharmacy. No laboratory. No prescriber. No medical group. No compounding class.
The site does talk about pharmacies. Every peptide page says "Longevixx protocols are prepared by licensed compounding pharmacies in the United States", and its closing panel says your therapy "is prepared by a partner compounding pharmacy". The terms treat "the Pharmacy" as a party to your agreement. None of them says which pharmacy, and neither "503A" nor "503B" appears on any page.
The nearest thing to a quality statement is a line that compounding pharmacies "are regulated by state boards and the FDA". That describes the category. It is not a result for anything Longevixx sells, and no potency, purity or sterility result appears anywhere on the site.
What the refund terms say
The terms carry a short refund policy. You can cancel a prescription order within 24 hours of placing it, provided the provider network has not yet received it. After that, orders "cannot be canceled due to the nature of the products", and no refund is issued for medication already dispensed or delivered.
Refunds are limited to five situations: the wrong medication was sent, it arrived damaged, it "does not meet required safety standards", it has not shipped, or "The prescribing Provider declines to issue a prescription." That last one backs the homepage's "$0 if you're not approved". Any medication you send back carries a $35 disposal fee.
What the trials show
Of the four molecules, two have completed phase 3 trials and two have no trial for the use they are sold for.
Tesamorelin — two completed phase 3 trials, 675 participants, studying visceral fat in HIV-associated lipodystrophy. 3 Sold here for "the deep abdominal fat that resists diet and training".
PT-141 — RECONNECT 1 and 2, 1,437 premenopausal women with hypoactive sexual desire disorder, the basis of an FDA approval. 5 Sold here "in women and men alike".
Sermorelin — 19 randomized trials, newest from 2005, every one measuring growth hormone secretion or growth in children. 1 Sold here for "restorative rest, recovery, and the sense of vitality". Only the growth-hormone release is the tested part.
NAD+ — no randomized trial of injected NAD+ in PubMed. 2 The human literature is about oral precursors, which are different molecules. Sold here to support "steadier day-long physical and mental energy".
What this means if you are buying
The evidence problems here belong to the molecules, and they are the same problems anywhere you buy them. The problems that belong to this seller are about checking: nothing to read, nobody named, and a narrow window to back out once an order is placed.
Questions
Frequently asked questions
Does Longevixx publish test results?
No. No page on the site mentions a "certificate of analysis" or "COA", and no potency, purity or sterility result appears anywhere. The only quality statement is that compounding pharmacies "are regulated by state boards and the FDA", which describes the industry rather than any product.
Which pharmacy compounds these peptides?
The site never says. Its peptide pages say the medicines are "prepared by licensed compounding pharmacies in the United States", and its terms refer to "the Pharmacy", but no pharmacy is named anywhere, and the words 503A and 503B do not appear.
Which peptides does Longevixx sell?
Four: tesamorelin at $299 a month, sermorelin at $249, PT-141 at $249, and NAD+ at $199. Each is prescribed only after a licensed provider reviews your assessment. The same site also sells GLP-1 weight-loss plans.
Which of these actually has evidence behind it?
Tesamorelin and PT-141 have completed phase 3 trials, but tesamorelin's were in people with HIV-associated lipodystrophy and PT-141's in premenopausal women with low sexual desire — not the general adults this menu addresses. Sermorelin's trials measured growth hormone release, not the sleep and recovery it is sold for. Injected NAD+ has no randomized trial at all.
Can I get a refund if something goes wrong?
In a few cases. The terms allow a cancellation within 24 hours of ordering, and a refund if the wrong or a damaged product is sent, if it has not shipped, if it fails safety standards, or if the provider declines to prescribe. Medication already dispensed is not refunded, and anything you send back carries a $35 disposal fee.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. Longevixx publishes none.
- 503A
- The section of the Food, Drug, and Cosmetic Act covering a preparation compounded by a state-licensed pharmacy against a prescription for one named patient. This term appears nowhere on Longevixx's site.
Compare
Others selling what Longevixx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
- Pallas HealthAlso sells NAD+ (nicotinamide adenine dinucleotide) · 4 of 4 claims match the trials
- ShedAlso sells Sermorelin · 4 of 6 claims match the trials
- CareBareRXAlso sells NAD+ (nicotinamide adenine dinucleotide) · 2 of 4 claims match the trials
- EdenAlso sells Sermorelin · 3 of 6 claims match the trials
Ranked
The lists Longevixx is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Longevixx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.